A Study of TAK-341 in Treatment of Multiple System Atrophy
2期
已完成
NCT05526391
| 适应症 | Multiple System Atrophy |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Takeda |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 158 人 |
|---|
| 干预（药物） | TAK-341 |
|---|
| 开始日期 | 2022年11月16日 |
|---|
| 完成日期 | 2025年7月28日 |
|---|
| 结果公布日 | 2026年6月2日 |
|---|
摘要
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.
Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52
Baseline, Week 52 · score on a scale
| Placebo | 5.58 ± 0.64 score on a scale |
|---|
| TAK-341 | 5.54 ± 0.62 score on a scale |
|---|
| p-value | =0.961 |
|---|
| Least Square (LS) Mean Difference | -0.04 (95% CI -1.78–1.69) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。